They were awarded the patent June 2012 and it is good till Oct. 2027. If the Nda is filed in the next few months who cares. Since it is a test and meet all of the requirements there is a great chance for approval. With cancer cachexia in the mix plus all the trials for AEZS-108 ,royalties from Cetrotide coming in @ 25 million, ozarlix disorazo- z 'other compounds in the pipeline plus 30 million in cash this is a bargain @$1.60, 50 million market cap. Many bios are cheap until they are "discovered".